Literature DB >> 3002619

Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors.

R Kurzrock, G E Gallick, J U Gutterman.   

Abstract

Activation of the ras oncogene has been associated with a number of human tumors. In this study, expression of p21ras in different histological types of fresh primary bronchogenic carcinomas was examined. p21ras products were detected in all lung tissues that were analyzed. Only 1 of 23 tumors demonstrated aberrant migration of p21ras. In contrast, 10 tumors had substantially elevated levels of p21ras products with respect to the adjacent normal lung tissues and with respect to the other lung tumors. There was no correlation between increased ras protein expression and tobacco exposure of the patient or extent of disease at the time of diagnosis. However, 9 of 11 tumors with a squamous component as opposed to only 1 of 12 tumors belonging to other histological classifications demonstrated increased p21ras. These data suggest that, in bronchogenic carcinomas, mutations associated with structural abnormalities and aberrant migration of p21ras occur infrequently as compared to quantitative changes in p21ras. Furthermore, differential expression of c-ras products in primary human lung tumors correlates with pathological cell type, and may be a common event in squamous cell carcinomas, but not adenocarcinomas or small cell carcinomas of the lung.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3002619

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Modulation of neuroendocrine surface antigens in oncogene-activated small cell lung cancer lines.

Authors:  L A Doyle; M Mabry; R A Stahel; R Waibel; L H Goldstein
Journal:  Br J Cancer Suppl       Date:  1991-06

2.  Monoclonal antibody specific for an activated RAS protein.

Authors:  W P Carney; D Petit; P Hamer; C J Der; T Finkel; G M Cooper; M Lefebvre; H Mobtaker; R Delellis; A S Tischler
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

3.  Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells.

Authors:  A M Pfeifer; G E Mark; L Malan-Shibley; S Graziano; P Amstad; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

4.  Detection of ras oncogenes by analysis of p21 proteins in human tumor cell lines.

Authors:  J Fujita; O Yoshida; Y Ebi; H Nakayama; H Onoue; J S Rhim; Y Kitamura
Journal:  Urol Res       Date:  1988

5.  Distribution of Ha-ras alleles in patients with colorectal cancer and Crohn's disease.

Authors:  R Klingel; P Mittelstaedt; W G Dippold; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

6.  Expression of p21 ras gene products in breast cancer relates to histological types and to receptor and nodal status.

Authors:  P Querzoli; E Marchetti; A Bagni; A Marzola; G Fabris; I Nenci
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

7.  v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer.

Authors:  M Mabry; T Nakagawa; B D Nelkin; E McDowell; M Gesell; J C Eggleston; R A Casero; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

8.  Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors.

Authors:  D W Ye; J F Zheng; S X Qian; Y J Ma
Journal:  Urol Res       Date:  1993-01

Review 9.  Oncogene proteins as biomarkers in the molecular epidemiology of occupational carcinogenesis. The example of the ras oncogene-encoded p21 protein.

Authors:  P W Brandt-Rauf
Journal:  Int Arch Occup Environ Health       Date:  1991       Impact factor: 3.015

10.  Tumor cell heterogeneity: divided-colony assay for measuring drug response.

Authors:  T Kuczek; D E Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.